EQRx, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EQRX research report →
Companywww.eqrx.com
EQRx, Inc. , a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC.
- CEO
- Melanie I. Nallicheri
- IPO
- 2021
- Employees
- 362
- HQ
- Cambridge, MA, US
Price Chart
Valuation
- Market Cap
- $1.14B
- P/E
- 5.40
- P/S
- 0.00
- P/B
- 0.80
- EV/EBITDA
- -1.83
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 14.15%
- ROIC
- 30.77%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $205.49M · 326.57%
- EPS
- $0.43 · 326.32%
- Op Income
- $-355,877,000
- FCF YoY
- -57.06%
Performance & Tape
- 52W High
- $4.75
- 52W Low
- $1.58
- 50D MA
- $2.25
- 200D MA
- $2.05
- Beta
- 0.63
- Avg Volume
- 2.95M
Get TickerSpark's AI analysis on EQRX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 9, 23 | Casdin Eli | other | 755,766 |
| Nov 9, 23 | Casdin Eli | other | 5,488,164 |
| Nov 9, 23 | Casdin Eli | other | 8,110,001 |
| Nov 9, 23 | Casdin Eli | other | 101,010 |
| Nov 9, 23 | Nallicheri Melanie | other | 626,999 |
| Nov 9, 23 | Nallicheri Melanie | sell | 1,900,000 |
| Nov 9, 23 | Nallicheri Melanie | sell | 530,335 |
| Nov 9, 23 | Nallicheri Melanie | other | 626,999 |
| Nov 9, 23 | Nallicheri Melanie | sell | 3,851,147 |
| Nov 9, 23 | Nallicheri Melanie | sell | 1,253,999 |
Our EQRX Coverage
We haven't published any research on EQRX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate EQRX Report →